Progressive Care to Report First Quarter Financial Results on May 17, 2022
Progressive Care Inc. (OTCQB: RXMD) has announced an investor conference call scheduled for 4:30 PM ET on May 17, 2022. The call will provide shareholders with insights into the first quarter results, the company's vision for the remainder of 2022, and updates on their plans to uplist to Nasdaq. Shareholders can submit questions in advance, and a replay will be available post-call. The company specializes in personalized healthcare services, including prescription pharmaceuticals and tele-pharmacy.
- Scheduled investor conference call to discuss first quarter results and future plans.
- Plans for uplisting to Nasdaq, indicating potential growth opportunities.
- None.
Progressive Care Inc. Has Scheduled an Investor Conference Call for 4:30 PM ET on Tuesday, May 17, 2022
MIAMI, FL, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company (the “Company” or “Progressive Care”), is pleased to announce that the Company has scheduled an investor conference call for 4:30 PM ET on Tuesday, May 17, 2022.
Chairman and CEO, Alan Jay Weisberg, stated, “We are looking forward to providing our shareholders with our first quarter results, Company’s vision for the rest of 2022, and an update regarding our progress towards uplisting to Nasdaq.”
Those attending the investor conference call will have the opportunity to submit questions concerning the Company in advance to Stuart Smith of SmallCapVoice.Com, Inc. via e-mail: ssmith@smallcapvoice.com by 12:00 PM EST on Monday, May 16, 2022. The Company plans to address as many appropriate questions as possible.
To access the call:
Dial-In Number: 1-857-232-0157
Access Code: 422095
For those unable to participate in the live conference call, a replay will be available at https://www.smallcapvoice.com/clients/rxmd/. shortly after the call has concluded.
An archived version of the webcast will also be available https://progressivecareus.com/news/.
Progressive Care Inc.
Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
For more information about Progressive Care, please visit the company’s website.
Connect and stay in touch with us on social media:
Progressive Care Inc.
https://www.progressivecareus.com/
PharmCoRx
ClearMetrX
Forward-Looking Statements:
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Public Relations Contact:
Carlos Rangel
carlosr@pharmcorx.com
Investor Relations Contact:
ClearThink Capital
nyc@clearthink.capital
FAQ
What are the details of the investor conference call for RXMD?
What topics will be discussed during the RXMD investor conference call?
How can I submit questions for the RXMD investor conference call?
